Abstract:Objectives: Sentinel lymph node (SLN) mapping with indocyanine green (ICG) and near-infrared fluorescence imaging (NIRFI) has been described for cervical cancers. However, only small published series have evaluated the accuracy of this technique in this disease. The FIRES trial is a multicenter prospective cohort study including women undergoing hysterectomy and lymphadenectomy for endometrial and cervical cancer. Our objective was to evaluate the accuracy of this SLN mapping technique in detecting occult metastatic disease in cervical cancer among patients undergoing a standardized technique by surgeons at multiple centers.Methods: Patients with stage IA2 to 1B1 cervical cancer (all histologies) were enrolled in the study between February 2012 and July 2015. Patients received 1 mg of ICG intracervical injection and underwent SLN mapping using robotic NIRFI as well as completion pelvic lymphadenectomies. Negative SLN specimens underwent ultrastaging with immunohistochemistry to cytokeratin. Detection rate, sensitivity, and false-negative predictive value were calculated. Fisher exact test was used to compare dichotomous variables between node-positive and -negative groups. The study is registered with clinicaltrials.gov.Results: A total of 67 patients were enrolled at 10 centers by 17 surgeons. Of these, 14 patients (21%) had pelvic nodal metastases. In 60 patients, at least 1 SLN was detected (90%). The rate of bilateral mapping was 61%. Of the 11 patients with metastases who underwent mapping, 7 had positive SLNs (sensitivity 64%), with 4 patients having a false-negative SLN (7.5%), and a negative predictive value (NPV) of 92.5%. Of the 4 patients with false-negative SLNs, 3 mapped unilaterally with the positive non-SLN found on the unmapped side. One patient had an empty unilateral SLN specimen on final pathology (false-positive mapping). Patients who had failed bilateral mapping were significantly more likely to have positive lymph nodes (P = .01). Patients with true bilateral mapping had 100% sensitivity and NPV for detecting metastatic disease.Conclusions: Bilateral SLN mapping achieved with ICG and robotic NIRFI is associated with high accuracy in detecting metastatic cervical cancer. In the case of unilateral mapping or failed mapping, a side-specific complete lymphadenectomy should be performed. Objectives: Sentinel lymph node (SLN) mapping with indocyanine green (ICG) and near-infrared fluorescence imaging (NIRFI) has been described for cervical cancers. However, only small published series have evaluated the accuracy of this technique in this disease. The FIRES trial is a multicenter prospective cohort study including women undergoing hysterectomy and lymphadenectomy for endometrial and cervical cancer. Our objective was to evaluate the accuracy of this SLN mapping technique in detecting occult metastatic disease in cervical cancer among patients undergoing a standardized technique by surgeons at multiple centers. Methods: Patients with stage IA2 to 1B1 cervical cancer (all histologies) were enrolled in the study between February 2012 and July 2015. Patients received 1 mg of ICG intracervical injection and underwent SLN mapping using robotic NIRFI as well as completion pelvic lymphadenectomies. Negative SLN specimens underwent ultrastaging with immunohistochemistry to cytokeratin. Detection rate, sensitivity, and false-negative predictive value were calculated. Fisher exact test was used to compare dichotomous variables between node-positive and -negative groups. The study is registered with clinicaltrials.gov. Results: A total of 67 patients were enrolled at 10 centers by 17 surgeons. Of these, 14 patients (21%) had pelvic nodal metastases. In 60 patients, at least 1 SLN was detected (90%). The rate of bilateral mapping was 61%. Of the 11 patients with metastases who underwent mapping, 7 had positive SLNs (sensitivity 64%), with 4 patients having a false-negative SLN (7.5%), and a negative predictive value (NPV) of 92.5%. Of the 4 patients with false-negative SLNs, 3 mapped unilaterally with the positive non-SLN found on the unmapped side. One patient had an empty unilateral SLN specimen on final pathology (false-positive mapping). Patients who had failed bilateral mapping were significantly more likely to have positive lymph nodes (P = .01). Patients with true bilateral mapping had 100% sensitivity and NPV for detecting metastatic disease. Conclusions: Bilateral SLN mapping achieved with ICG and robotic NIRFI is associated with high accuracy in detecting metastatic cervical cancer. In the case of unilateral mapping or failed mapping, a side-specific complete lymphadenectomy should be performed.

Validation of Sentinel Lymph Node Biopsy in Robotic Endometrial Cancer Staging Surgery: Results From a High-Volume Center in India

Accuracy of robotic sentinel lymph node detection (RSLND) for patients with endometrial cancer (EC)

Sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology for endometrial cancer: A prospective study using a surgical algorithm in Indian patients

Laparoscopic Sentinel Lymph Node Mapping Using NIR Fluorescence with ICG in Early Endometrial Cancer: Experience at a Tertiary Care Oncology Centre

The safety and feasibility of minimally invasive sentinel lymph node staging using indocyanine green in the management of endometrial cancer

Robotic-Assisted Sentinel Lymph Node Mapping With Indocyanine Green in Pelvic Malignancies: A Systematic Review and Meta-Analysis

Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy.

Efficacy of Sentinel Lymph Node Mapping in Endometrial Cancer with Low- or High-Intermediate Risk

Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis

Bilateral SLN Mapping for Cervical Cancer with ICG and Robotic Fluorescence Imaging is Associated with Greater Accuracy in Detecting Metastatic Disease

Comparing Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Mapping in Endometrial Cancer: A Randomized‐controlled Single‐center Trial

Sentinel Node Mapping Using Indocyanine Green and Near-infrared Fluorescence Imaging Technology for Uterine Malignancies: Preliminary Experience With the Da Vinci Xi System

Sentinel lymph node biopsy guided by indocyanine green dye in endometrial cancer patients: literature review and clinical experience

A Prospective Study of Sentinel Lymph Node Mapping for Endometrial Cancer: is It Effective in High-Risk Subtypes?

Sentinel Lymph Node Biopsy is Feasible in Cervical Cancer Laparoscopic Surgery: A Single-Center Retrospective Cohort Study

Oncologic Outcome of Robotic-Assisted and Laparoscopic Sentinel Node Biopsy in Endometrial Cancer

A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer

The Evaluation of Sentinel Lymph Node Biopsy Using Radiocolloid in First Stage Endometrial Cancer

INTRA- AND EARLY POSTOPERATIVE RESULTS OF BIOPSY OF SIGNAL LYMPH NODE UNDER CONTROL OF ICG MAPPING IN PATIENTS WITH ENDOMETRIAL CANCER OF INITIAL STAGES

Comparing Surgical and Oncological Outcomes between Indocyanine Green (ICG) Sentinel Lymph Node Mapping with Routine Lymphadenectomy in the Surgical Staging of Early-Stage Endometrioid Endometrial Cancer